SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    -0.875 (-43.75%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £1.88m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Supply Agreement with SeaWith

19 Mar 2026 07:00

RNS Number : 2085X
BSF Enterprise PLC
19 March 2026
 

19 March 2026

 

BSF Enterprise PLC

 

3D Bio-Tissues Limited ("3DBT")

Signs Commercial Supply Agreement with SeaWith

BSF Enterprise PLC (LSE: BSFA) (the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce that its subsidiary, 3D Bio-Tissues Limited ("3DBT"), has entered into a five-year commercial Supply Agreement (the "Agreement") with SeaWith, a pioneering South Korean biotechnology company specializing in cultivated meat.

 

Strategic Partnership and Value Creation

 

The Agreement establishes a long-term commercial framework for the supply of 3DBT's proprietary City-Mix®, a premium macromolecular crowder designed to enhance cell culture efficiency. This partnership represents a significant milestone in expanding the market reach of City-Mix® into the global cultivated protein sector.

 

· Contract Value: The total value of the Agreement to 3DBT is estimated at approximately £300,000 over the contract term.

· Operational Integration: 3DBT will provide a regular supply of City-Mix® to support SeaWith's production pipeline for its flagship Welldone™ cultivated beef product.

· Cost Efficiency: City-Mix® is expected to significantly lower production costs for SeaWith by reducing the requirement for expensive growth media by approximately 30%.

· Growth Trajectory: The Agreement supports a phased scale-up of supply volumes through 2030, aligning with SeaWith's transition toward large-scale commercial production facilities.

 

About SeaWith

Founded in 2019 and headquartered in South Korea, SeaWith is a biotechnology innovator that has raised over $8 million in venture funding to date. The company utilizes seaweed-derived technologies to produce sustainable, slaughter-free meat alternatives, focusing on scalability and the reduction of environmental impact. SeaWith is a designated operator under South Korea's Gyeongbuk Cell-Cultured Food Regulatory Free Zone, reflecting the company's leadership in advancing cultivated food innovation within a government-supported regulatory framework.

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:

 

https://bsfenterprise.com/link/Pqnkoy

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Shard Capital (Broker)

Damon Heath

Isabella Pierre

 

(0)20 4530 6926

(0)20 4530 6928

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRMZGMFNRDGVZM
Date   Source Headline
12th Jun 20267:00 amRNSParis Auction Result
11th Jun 20267:00 amRNS£1 Million Convertible Loan Note
8th Jun 202611:59 amRNSShareholder meeting results
3rd Jun 20267:00 amRNSConditional Further Investment
2nd Jun 20268:50 amRNSTechnical White Paper on T-Rex Leather™
28th May 20267:00 amRNSAuction Update - May 2026
26th May 20267:00 amRNSStrategic Update May 2026
22nd May 20263:13 pmRNSPosting of Circular and Notice of General Meeting
5th May 20267:00 amRNST-Rex Leather™ handbag to be auctioned
17th Apr 202610:00 amRNSAdmission of Shares
13th Apr 20267:00 amRNSStrategic Shareholding Update
7th Apr 20267:00 amRNSWorld’s First T-Rex Leather Handbag Unveiled
2nd Apr 20267:00 amRNSWorld First T-Rex Leather™ Product
19th Mar 20267:00 amRNSSupply Agreement with SeaWith
17th Mar 20267:00 amRNSLGL Tanning Milestones
17th Mar 20267:00 amRNSLGL Tanning Milestones
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
3rd Mar 202611:00 amRNSResult of Annual General Meeting
27th Feb 20267:00 amRNSUpdate on Proposed Equity Fundraise
9th Feb 20267:00 amRNSNotice of 2026 AGM
3rd Feb 20265:14 pmRNSAnnual Financial Report - Correction
2nd Feb 20267:00 amRNSAnnual Financial Report
19th Jan 20267:00 amRNSKERATO LIMITED SIGNS WITH QUEBEC PSO GRANT
17th Dec 202511:08 amRNSResult of General Meeting
16th Dec 20257:00 amRNS3D Bio-Tissues Signs Supply Agreement with SeaWith
15th Dec 20257:00 amRNSChanges to timetable for proposed Equity Fundraise
5th Dec 20259:50 amRNS-RBSF Enterprise launches new Investor website
1st Dec 20257:02 amRNSProposed Equity Fundraise - Strategic Direction
1st Dec 20257:00 amRNSEquity Fundraise & Notice of General Meeting
29th Aug 202510:47 amRNSResignation of Chairman
10th Jul 20257:00 amRNSAgreement
25th Jun 20257:00 amRNSInterim 2025 Results
23rd May 20257:00 amRNS15p Warrants Amended
21st May 20257:00 amRNSLab-Grown Leather Ltd Progress
28th Apr 202510:01 amRNSStrategic Investment
25th Apr 20259:48 amRNSJoint Venture
13th Mar 20257:00 amRNS3DBT Lab Grown Leather Commercialization
6th Mar 20253:51 pmRNSPublication of a Prospectus
5th Mar 202512:10 pmRNSResult of Annual General Meeting
11th Feb 20258:21 amRNSExpected admission of shares - Replacement
11th Feb 20257:00 amRNSAIM Admission - Update
10th Feb 20257:00 amRNSAGM Statement
31st Jan 202512:41 pmRNSAnnual Financial Report
31st Jan 202512:31 pmRNSAnnual Financial Report
21st Jan 20257:00 amRNSBSF Enterprise and Sartorius
27th Dec 20247:00 amRNSAdmission of Placing Shares
18th Dec 20247:00 amRNS3DBT Ltd Secures Prestigious Northern Accelerator

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.